Tango Therapeutics Inc

Crystal Adam’s dual buy‑sell trade at Tango Therapeutics signals insider confidence: buy at $5.20, sell at $25, and liquidate options—showing a bullish stance amid strong upside potential.

Crystal Adam’s March 2026 sale of 20,251 Tango shares is a routine Rule 10b‑5 move amid strong trial data and a new Erasca partnership—no red flags yet.

Crystal Adam’s 54,345‑share sale at $12.77 shows disciplined liquidity planning, boosting Tango’s options exposure ahead of Q4 earnings and future growth.

Insider buys at Tango Therapeutics signal confidence in its rare‑disease pipeline, highlighting strategic alliances, orphan‑drug advantages and a bullish outlook for investors.